Xanthine Oxidase
XO
Xanthine oxidase (XO), a versatile molybdoflavoprotein, catalyzes the oxidative hydroxylation of purine substrates (hypoxanthine and xanthine) to produce uric acid and subsequent reduction of oxygen at the flavin center with the generation of reactive oxygen species, either superoxide anion radical or hydrogen peroxide.
Xanthine oxidase is an important enzyme of purine catabolism pathway and has been associated directly in pathogenesis of gout and indirectly in many pathological conditions like cancer, diabetes and metabolic syndrome. The selective inhibition of xanthine oxidase may result in a broad spectrum therapeutic use for gout, cancer, inflammation and oxidative damage.
All Product Categories
-
Xanthine Oxidase Related Products (159)
Related Products (159)
-
Antibodies (1)
-
Xanthine oxidase-IN-13
0 ImagesCat. No.: HY-161455Xanthine oxidase-IN-13 (Compound 10) is a selective xanthine oxidase inhibitor (IC50: 149.56 μM for bovine xanthine oxidase). Xanthine oxidase-IN-13 can be used for research of inflammatory arthritis.
-
Xanthine oxidase-IN-23
0 ImagesCat. No.: HY-182000CAS No.: 3055112-52-9Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type Xanthine oxidase inhibitor with an IC50 of 3.33 μM. Xanthine oxidase-IN-23 directly binds to XOD in a reversible mixed-type manner to inhibit its catalytic activity. Xanthine oxidase-IN-23 upregulates ABCG2 and downregulates GLUT9 to promote renal urate excretion. Xanthine oxidase-IN-23 reduces serum urate levels and improves renal function in hyperuricemic mice. Xanthine oxidase-IN-23 can be used in the research of hyperuricemia.
-
Antioxidant agent-13
0 ImagesCat. No.: HY-155123CAS No.: 2966778-87-8Antioxidant agent-13 (Compound 5f) is an antioxidant agent. Antioxidant agent-13 inhibits DPPH and FRAP with IC50s of 80.33 and 85.69 μM. Antioxidant agent-13 also inhibits LOX and XO enzymes with IC50s of 16.85 and 23.01 μM.
-
Xanthine oxidase-IN-16
0 ImagesCat. No.: HY-162961Xanthine oxidase-IN-16 is potent and orally active xanthine oxidase (XO) inhibitor with an IC50 of 102 nM. Xanthine oxidase-IN-16 shows significant efficacy in hyperuricemia rats.
-
2,6-Dihydroxyacetophenone (Standard)
0 Images2,6-Dihydroxyacetophenone (Standard) is the analytical standard of 2,6-Dihydroxyacetophenone (HY-Y0106). This product is intended for research and analytical applications. 2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC50 of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia.
-
Xanthine oxidase-IN-19
0 ImagesCat. No.: HY-179030CAS No.: 3055301-22-6Xanthine oxidase-IN-19 (Compound 13i) is an orally effective inhibitor of xanthine oxidase (XO), with an IC50 of 0.2 μM. Xanthine oxidase-IN-19 can significantly reduce serum uric acid levels in acute hyperuricemia rat models. Xanthine oxidase-IN-19 can be used for the study of acute hyperuricemia.
-
Baicalein hydrate
0 ImagesCat. No.: HY-N0196ACAS No.: 352000-07-8Synonyms: 5,6,7-Trihydroxyflavone hydrateBaicalein hydrate (ALA; C18:3 (9Z,12Z,15Z); C18:3 n-3) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.
-
Nequinate
0 ImagesCat. No.: HY-116433CAS No.: 13997-19-8Nequinate, a quinoline compound, is an anticoccidial agent against cecal coccidiosis (Eimeria tenella) infections. Nequinate inhibits xanthine oxidoreductase (XOD) activity.
-
Xanthine oxidase-IN-20
0 ImagesCat. No.: HY-180186CAS No.: 3069916-11-3Xanthine oxidase-IN-20 is a potent and orally active xanthine oxidase (XO) inhibitor with an IC50 of 1.7 nM. Xanthine oxidase-IN-20 exhibits outstanding serum uric acid (SUA)-lowering efficacy in both mouse and rat acute hyperuricemia models. Xanthine oxidase-IN-20 shows favorable safety profile. Xanthine oxidase-IN-20 can be used for hyperuricemia and gout research.
-
Isorhamnetin-3-O-neohespeidoside (Standard)
0 ImagesCat. No.: HY-N0778RCAS No.: 55033-90-4Isorhamnetin-3-O-neohespeidoside (Standard) is the analytical standard of Isorhamnetin-3-O-neohespeidoside (HY-N0778). This product is intended for research and analytical applications. Isorhamnetin-3-O-neohespeidoside is a flavonoid. Isorhamnetin-3-O-neohespeidoside can be isolated from Typha angustifolia. Isorhamnetin-3-O-neohespeidoside inhibits xanthine oxidase activity with an IC50 of 48.75 μg mL. Isorhamnetin-3-O-neohespeidoside has antioxidant and osteoclastogenic activities. Isorhamnetin-3-O-neohespeidoside can be used in research of bone.
-
Ilexoside O
0 ImagesCat. No.: HY-N9324CAS No.: 136552-23-3Ilexoside O is a triterpene saponin isolated from the roots of Ilex pubescens. Ilexoside O exhibits weak xanthine oxidase (XOD) inhibitory activity (IC50=53.05 μM).
-
CC15009
0 ImagesCat. No.: HY-162882CAS No.: 2482713-67-5CC15009 is a xanthine oxidoreductase (XOR) inhibitor, with an IC50 value of 0.237 nM. CC15009 can inhibit the oxidative subtype of XOR, thereby reducing the production of the byproduct ROS and exhibiting antioxidant activity. CC15009 has demonstrated a good dose-dependent uric acid-lowering effect in two different mouse models of hyperuricemia induced by XOR substrates.
-
Febuxostat acyl glucuronide
0 ImagesCat. No.: HY-129889CAS No.: 1351692-92-6Synonyms: Febuxostat acyl-β-D-glucuronideFebuxostat acyl glucuronide (Febuxostat acyl-β-D-glucuronide) is a metabolite of Febuxostat (HY-14268). Febuxostat is a potent, selective and non-purine xanthine oxidase (XO) inhibitor.
-
Smilaxchinoside A
0 ImagesCat. No.: HY-N17914CAS No.: 935530-84-0Smilaxchinoside A is an orally active steroidal glycoside found in the roots of S. riparia. Smilaxchinoside A reduces serum uric acid levels and shows potent uricosuric activity. Smilaxchinoside A inhibits XOD activity and downregulates renal mURAT1 expression. Smilaxchinoside A can be used for the research of hyperuricemia.
-
Fraxamoside
0 ImagesCat. No.: HY-N3906CAS No.: 326594-34-7Fraxamoside is a competitive xanthine oxidase inhibitor with an IC50 of 16.1 μM and a Ki of 0.9 μM.
-
CV 3611
0 ImagesCat. No.: HY-106797CAS No.: 98829-12-0CV 3611 is a potent and orally active free radical scavenger. CV 3611 shows anti-inflammatory, antiarrhythmic and anticancer effects. CV 3611 can be used for the researches of cancer, inflammation and cardiovascular disease, such as hepatocellular carcinoma and acute pancreatitis.
-
Aurantiamide benzoate
0 ImagesAurantiamide benzoate is a nature product that could be isolated from two tropical medicinal plants, Cunila spicata and Hyptis fasciculata. Aurantiamide benzoate is a potent xanthine oxidase inhiobitor with an IC50 value of 70 μM.
-
Xanthine oxidase-IN-24
0 ImagesCat. No.: HY-189143Xanthine oxidase-IN-24 is an orally active mixed-type inhibitor of xanthine oxidase, with an IC50 of 0.051 μM and a Ki of 0.162 μM. Xanthine oxidase-IN-24 interacts with both free xanthine oxidase and the xanthine-xanthine oxidase complex, and reduces uric acid production in vivo. In a rat model of hyperuricemia induced by Potassium oxonate (HY-17511), Xanthine oxidase-IN-24 dose-dependently lowers serum uric acid levels, improves renal function-related biochemical parameters such as creatinine and urea nitrogen, and alleviates histopathological damage to liver and kidney tissues. Xanthine oxidase-IN-24 can be used in the research of hyperuricemia.
-
Xanthine oxidoreductase-IN-3
0 ImagesCat. No.: HY-151973CAS No.: 651769-78-7Xanthine oxidoreductase-IN-3 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 26.3 nM. Xanthine oxidoreductase-IN-3 can be used for the research of acute hyperuricemia.
-
Xanthine oxidase-IN-5
0 ImagesCat. No.: HY-144456CAS No.: 2276711-87-4Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model.
